Reversal of Warfarin-Induced Coagulopathy with Kcentra
Mechanism of Action
- Kcentra, a four-factor prothrombin complex concentrate (4F-PCC), directly replaces vitamin K-dependent clotting factors (II, VII, IX, and X) and anticoagulant proteins C and S, providing immediate restoration of coagulation factor levels to reverse warfarin-induced coagulopathy, as recommended by the American College of Chest Physicians 1, 2
- The American College of Chest Physicians suggests that 4F-PCC does not require cross-matching, thawing, or large volume infusion, and can be administered in 15-30 minutes 1
- The product is virally inactivated and does not pose risk of volume overload, according to the American College of Chest Physicians 1
Pharmacodynamic Effects
- The American College of Chest Physicians recommends that PCC provides immediate correction of INR, typically within 15-60 minutes of administration, with a strength of evidence rated as high 1, 2
- Factor VII has the shortest half-life at approximately 4 hours, while Factor II has the longest half-life at approximately 60 hours, as reported by the World Journal of Emergency Surgery 4
- This differential creates potential for rebound coagulopathy if vitamin K is not co-administered, with a strength of evidence rated as moderate 3, 4
Reversal of Anticoagulation
- The American Heart Association states that PCCs are highly effective for reversing vitamin K antagonist (warfarin) anticoagulation by directly replacing depleted clotting factors, with a strength of evidence rated as high 1, 2
- The European Society of Cardiology recommends that specific reversal agents (andexanet alfa for Xa inhibitors, idarucizumab for dabigatran) are required for DOAC reversal, with a strength of evidence rated as high 4
Essential Co-Administration Requirement
- The American College of Chest Physicians recommends that vitamin K (5-10 mg IV) must always be administered with Kcentra to prevent rebound coagulopathy, with a strength of evidence rated as high 4, 3
- Vitamin K stimulates endogenous factor synthesis, which takes 4-24 hours but provides sustained reversal, as reported by the American College of Chest Physicians 1, 2